Kura Oncology, Inc.

KURA

NASDAQ

Healthcare

Biotechnology

San Diego, CA, US192 employeeskuraoncology.com

$8.62

+0.28(3.36%)

52W $5.54 – $12.14

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.

Revenue breakdown: License And Collaboration Revenue (49.1%), Collaboration Revenue (49.1%), Product (1.8%).

$761MMkt Cap

$68MRev TTM

-$280MNI TTM

-2.6xP/E TTM

What Changed Recently

Financial Results

Mar 4, 2026

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as

View filing →

Charter Amendment

Jan 28, 2026

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the

View filing →

Financial Results

Jan 11, 2026

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Revenue by Segment

License And Collaboration Revenue49.1%($119M)

Collaboration Revenue49.1%($119M)

Product1.8%($4M)

Analyst View

Peer Companies

Company	Price	Change	Market Cap	P/E
TNGXTango Therapeutics, Inc.	$21.66	+2.07%	$2.5B	-21.7
TYRATyra Biosciences, Inc.	$39.38	+2.89%	$2.1B	-18.1
BCAXBicara Therapeutics Inc. ...	$21.48	+4.78%	$1.2B	-8.3
SVRASavara Inc.	$5.57	-0.27%	$1.1B	-9.5
EYPTEyePoint Pharmaceuticals,...	$13.41	+3.00%	$1.1B	-4.6
MRVIMaravai LifeSciences Hold...	$2.96	+2.96%	$812M	-3.4
REPLReplimune Group, Inc.	$8.27	+8.61%	$682M	-2.0
PRMEPrime Medicine, Inc.	$3.31	-2.36%	$598M	-2.6

Company Profile

CIK0001422143

ISINUS50127T1097

CUSIP50127T109

Phone858 500 8800

Address12730 High Bluff Drive, San Diego, CA, 92130, US

SEC EDGAR